This is the authors' abstract. We don't add key points for this paper.
Transforming homogeneous olefin hydroformylation into a robust heterogeneous process is hindered by Rh leaching and CO-induced suppression of H2 activation. Here, we report a dual-site RhFeSAA+NA/hydroxyapatite (HAP) catalyst featuring spatially differentiated RhFe single-atom alloy (SAA) and nanoalloy (NA) sites that overcomes the fundamental conflict between CO tolerance and reactivity. This cooperative architecture delivers >99% conversion and selectivity for styrenic and α-olefins (C6–C10) at 60 °C, and a TOF of 30,225.9 h–1 for propene hydroformylation at 110 °C with excellent antileaching ability. Mechanistic and operando studies reveal that the RhFe nanoalloy sites remain robust under CO-rich conditions to facilitate H2 dissociation, while neighboring single-atom alloy sites mediate the catalytic cycle. Hydrogen spillover from NA sites reconstructs the defect-rich Fe-HAP interface, creating a phosphate hydroxyl microenvironment that stabilizes interfacial CO and provides a local reservoir for carbonyl insertion. These findings demonstrate that dual-site catalysis coupled with interfacial engineering can bypass competitive adsorption in complex multisubstrate transformations.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: